Category Archives: whatsnew

Oncologists’ Treatment Rationale and Wish-List in IO

The latest release from our annual corporate leadership reveals multiple factors supporting the use of an IO approach having similar impact on treatment decisions. Factors most driving oncologist usage were efficacy and quality of life benefits offered by IO treatments followed by label safety and availability of biomarkers. With little geographical difference, US oncologists stressed more importance on the rate of disease progression compared to their EU based colleagues.

Click to Enlarge

Oncologists also shared that information about efficacy is their most desired area for improvement by pharma. Information on side effects and use in expanded indications for earlier disease were preferred more by EU based physicians whilst US colleagues stressed greater importance on quality of life and real-world evidence.

About the study

The 2020 Corporate Leadership Study was conducted with 100 oncologists across US and EU using ONCpulseTM  agile research solution. ONCpulseTM answers today’s business questions tomorrow through global access to 130,000+ experts and treaters in oncology, hematology and complex rare diseases.

The objectives of the study were:

  • Defining what ‘corporate leadership’ means to the oncology community
  • Revealing the leaders (in oncology and IO) and an evaluation of their performance by oncologists
  • Assessing current barriers and drivers to IO treatment choice and identifying oncologist views on areas for needed improvement by pharma.

Clients like you invest in MDoutlook as their partner of choice thanks to the positive accolade garnered from praise across the industry.

Want a report copy? Sign up by clicking here.

If you would like a personalized leadership briefing and map out your teams future success, let’s take the next step to arrange a meeting using the Calendly link or by contacting us at [email protected] or via +1 404 496 4136.

Mastering Virtual Conference Data Presentation Impact

With ASCO announcing their inaugural virtual program last week and ahead of other major oncology and hematology conferences (such as EHA) moving online, client appetite for planning their activities have not abated in hiring us to measure impact of their data announcement activity in the current “new norm”.

Have you planned measurement of your upcoming virtual conference activity?

Irrespective of the meeting format, measuring data announcement impact is more important than ever. With the deluge of scientific data presentations planned, clients are eager to assess the effectiveness of the virtual conference format and assess the impact of their activities in breaking through the competitive noise. Through access to the largest validated global online community of 130,000+ ThoughtLeaders and treaters (in oncology, hematology and complex rare diseases) are we able to get to your core targets to evaluate whether announcements change oncologists’ behavior and estimate how a data presentation influences their future treatment decisions and clinical practice.

Be the first to know!

Clients often find themselves in a situation where they need to quickly understand the implications of their own and competitors’ conference data announcements. For one of our clients we recruited 500 oncologists across 30 countries within a week of the conference via our agile ONCpulseTM research service. Timely access to the results allowed our client to confidently react quickly to our insights! Often, we are the first to offer in-depth results after a congress.

Client feedback

“Rapid results allowed us to adapt our commercialization plans for the following year and assess success of our own data announcements. This is very useful for us in light of next year’s planning”.

Brand Director Oncology, Major Pharmaceutical Company

Tracking your impact post conference matters

Whilst measuring conference impact is important, tracking follow-up activity from a conference is of even greater importance and should not be overlooked when assessing the influence and reach of your messages. In the current “new-norm”, these channels for communication will be less affected!

Conference data announcements speak volumes and the virtual format will similarly be as impactful. However, the importance of measuring follow-up and impact from messaging activity post-conference is neatly highlighted from a client survey of 147 US oncologists in showing little difference with attention captured at conferences when compared to post-conferences.

Click to Enlarge

About half (n=75) of US oncologists who did not attend the conference rated their awareness of the news as relatively high. Nearly two-thirds of academic non-attendees rated their awareness of conference results as high or very high and by comparison, still almost half of US community oncologists rated their level of awareness on a similar basis. We must not forget that non-attendees choice for staying up-to-date of information post conference will in most cases be via digital communication channels and least affected by the current situation.

Conference research specialists

Are you currently facing the challenge of measuring the impact of your scientific data presentation in the “new-norm”? For clients like you we make this process easy. With 10+ years’ experience and more than 140 projects under our belt, take the next easy step to meet using the calendar link or contact us at [email protected] or call +1.404.496.4136.

Choose MDoutlook to measure the success of your scientific data presentation.

Leadership Success in IO from Oncologists’ Perspectives

Having recently named the 2020 leaders in oncology and ImmunoOncology, our latest release from our annual Corporate Leadership report reveals the key attributes oncologists view as driving successful leadership in IO.

Click to Enlarge

“Products” and “R&D/Product Pipeline” are the two most important aspects driving oncologists’ view of Corporate Leadership. The top five domains account for 73% of Oncologists’ definition of leadership in ImmunoOncology (IO) and include “Patient Support”, “Corporate Commitment” andCustomer Service”.

Engaging oncologists from the EU and US, we found a high consistency in their response but there were also notable differences:

  • US oncologists stressed higher importance on “Customer Service” ranking it 3rd compared to 7th amongst EU oncologists
  • EU oncologists favoured “MSLs / Medical Affairs” higher than their US colleagues (ranking 5th vs 8th in US)

Direct customer engagement performed through life science companies commercial and marketing activities account for 35% of oncologist’s preferred domains.

To get your copy of the 2020 Corporate Leadership report, please click here to request your report copy.

About the study

The 2020 Corporate Leadership Study was conducted with 100 oncologists across US and EU using ONCpulseTM agile research solution. ONCpulseTM answers today’s questions tomorrow through global access to 130,000+ experts and treaters in oncology, hematology and complex rare diseases.

The objectives of the research were to:

  • Define the meaning of ‘corporate leadership’ to the oncology community
  • Reveal the leaders in oncology and ImmunoOncology (IO) to compare/contrast how companies are evaluated by oncologists
  • Assess current barriers and drivers to ImmnoOncology treatment use and identify what oncologists would like to see improved by corporate leaders in the IO space

Clients like you choose MDoutlook as their precision intelligence partner of choice though the winning solutions and team expertise that has garnered praise from across the industry. If you would like your personalized leadership briefing and map out your teams future success, lets take the next step to arrange a meeting using the calendar link or contact us today at [email protected] or call +1.404.496.4136.

Unveiling 2020 Leaders in Oncology & IO

In our latest annual series exploring corporate leadership (in oncology and IO), oncologists shared their views to reveal BMS (and Celgene), Merck & Co and Roche / Genentech as dominant in oncology and ImmunoOncology.

Click on image to enlarge

Today’s corporate leaders dominated in 2019 with oncologist preferences showing consistency in their ranking companies (year on year) with one notable change as Pfizer dropped out the 2020 top 3 leaders in EU oncology.

Oncologists chose to rate corporate leadership across a greater number of companies in oncology compared to a tighter list of companies they rated in ImmunoOncology.

Leadership was determined through triangulation of three robust approaches. IO corporate leadership patterns were more distinct with clear leaders (compared to oncology) across tumor types.

  • BMS ranked first in IO tumor types including AML, Hodgkin’s lymphoma, Multiple myeloma, HCC, Pancreatic, Kidney, Melanoma and Head & Neck cancers
  • Roche / Genentech was rated top in B-cell lymphomas, Breast (including HER2+, HR+ & TN), Bladder and SCLC
  • Merck & Co made IO pole position in Colorectal, NSCLC and Prostate cancer

Around half of US (50%) and EU (58%) oncologists view corporate leadership in IO broadly, and the other half view corporate leadership by individual tumor types.

Our next post will explore attributes oncologists viewed as driving successful corporate leadership.

About the study

The 2020 Corporate Leadership Study was conducted with 100 oncologists across US and EU using ONCpulseTM agile research solution. ONCpulseTM  answers today’s questions tomorrow through global access to 130,000+ experts and treaters in oncology, hematology and complex rare diseases.

The objectives of the research were to:

  • Define the meaning of ‘corporate leadership’ to the oncology community
  • Reveal the leaders in oncology and ImmunoOncology (IO) to compare/contrast how companies are evaluated by oncologists
  • Assess current barriers and drivers to ImmunoOncology treatment use and identify what oncologists would like to see improved by corporate leaders in the IO space

Want to find out more? Click here to get your copy of the 2020 Corporate Leadership report .

We breed client confidence as a leading precision intelligence company through winning solutions and team expertise. Lets discuss your and your teams future leadership success. Take the next step to arrange a meeting using the calendar link or contact us today at [email protected] or call +1.404.496.4136.

Driving ThoughtLeader Activation in Your Brand Journey

Most life science companies strategize to engage ThoughtLeaders with the majority of clients deploying engagement strategies during Phase 3 / launch. A small number target influential ThoughtLeaders earlier (pre-clinical/pre-launch) building long-term valuable relationships (‘brand ambassadors”) within scientific and physician communities.

Along the product journey, MDoutlook empowers clients by engaging experts and treaters at different stages through superior approaches to identification, mapping and activation.

Right ThoughtLeader and Treater

Clients hire us to hyper-target experts and treaters that matter most in their journey whether driving impactful commercialization strategies or engaging influential scientific experts during pre-launch. With an unparalleled global community, we instantly access clinicians (including niche targets) to your competitive advantage.

Click to enlarge

Right information, right time

Making confident decisions on-the-go matters most to our clients who regularly choose us to be there for them when it matters most with meaningful precision intelligence!

  • Improving targeting or call planning, we support sales activity planning through immediate identification or verification of valuable experts and treaters
  • Through rich profiling, finding influential scientific ThoughtLeaders in your brand journey to involve with e.g. clinical trials, medical publications or scientific conferences
  • Optimizing expert collaborations at the (inter)national, national and local level from mapping network behind networks for maximum impact!

Rapid activation

Clients retain us knowing quick and easy wins to activating experts and treaters are consistently delivered

  • Answering today’s questions, tomorrow via ONCpulse studies
  • Through powerful and actionable insights e.g. navigating brand performance in competitive markets through hybrid KPI / ATU tracking

Clients judge us on successful outcomes:

  • For one client, we measured conference data impact in a week via insights from 500 top oncologists, worldwide. “Rapid results allowed us to adapt our commercialization plans and assess the success of our own data announcements. This is very useful for next years’ planning” Brand Director Oncology, Major Pharmaceutical Company.
  • For another client, using our Oncology community, we activated highly influential ThoughtLeaders across five countries in Asia, for an Ad Board to ascertain messages resonating with those on the ‘decision edge’ in Hepato-Cellular Carcinoma (HCC)

We breed client confidence as a leading precision intelligence company with transparent solutions and team expertise. Let’s take a positive step together to make 2020 a success for you, your brand and business! Contact us today at [email protected] or call +1 404.496.4136. to arrange a meeting.

Accelerating precision engagement

In 2019 MDoutlook engaged over 87,000 cancer treaters to solve their critical business pain points with game-changing precision intelligence and actionable recommendations.

Over the past year, we have helped more clients than ever with timely critical input to their business.  Through our validated and active community of cancer treaters and ThoughtLeaders, we engaged 87,000 physicians worldwide.

We have helped clients make confident business decisions in the following ways.

Precision ThoughtLeader identification and mapping

Click to enlarge

Timing is everything in today’s highly competitive environment. Our clients have immediate access to 14,000+ ThoughtLeaders and 120,000+ treaters in more than 60 cancer types across solid tumors, hematological disorders, rare tumor types:

  • For one of our clients, we analyzed 1,300 US physician-reported patient outcomes of GI tumor types leading to interesting insights. Academic ThoughtLeaders, on average, saw 20% more patients than community-based ThoughtLeaders.

.

Impactful KPI and ATU tracking 

Click to enlarge

During 2019, we helped Brands’ success by tracking and anticipating market dynamics through highly focused and customized KPI /ATU projects delivering impactful insights and actionable recommendations:

  • For one of our clients, we analyzed 8 key EU markets using our tailored KPI measurement approach, helping them triple their market share in 18 months, generating north of €100m in additional sales.
  • For another client, we launched a ground-breaking study in hemophilia to measure their brand’s health in a dynamic market through our hybrid ATU-KPI approach across 17 countries reaching more than 420 hematologists.

Dynamic ONCpulse surveys

Clients utilized our agile and adaptive service, ONCpulse, to conduct micro quantitative and qualitative research when needing to answer today’s critical business questions tomorrow:

  • One of our clients, reflecting on an ONCpulse project interviewing 50 Oncologists’ in metastatic gastric cancer, said “This is great! Thanks. I appreciate the quick turnaround and will discuss the results with my ad agency on Wednesday.” Marketing Director of a large BioPharmaceutical Company.
  • For another client, we used our community of treaters to help them interview 30 oncologists in a hard-to-find-group focusing on 2nd line treatments in head & neck cancer.

Let’s take the next step to discuss our contribution to your success in 2020. Contact us today at [email protected] or call at +1 404.496.4136 to arrange a meeting.

Click to enlarge

Meet MDoutlook at an upcoming conference.

We will be at the EAHAD annual meeting (5th to 7th February 2020) in The Hague, Netherlands and look forward to meeting you if you are there.

2020 MDoutlook Leadership Report

Next month, we will release results from the latest wave of our leadership report in oncology and immuno-oncology.   More information about the 2020 Leadership Study will become available as we publish the read-out results.

Please contact us if you wish to be included in the distribution of the study.

Immediate access to your target ThoughtLeaders

Identifying the right experts is often lengthy and challenging for biopharmaceutical companies and their agencies. At MDoutlook, we streamline the process to gaining precision engagement to the expertise of over 14,000 ThoughtLeaders and 120,000+ qualified treaters in oncology, hematology and rare diseases from over 120 countries.

Timing is everything in today’s highly competitive environment. We can help you immediately access verified and active ThoughtLeaders available in more than 60 cancer types across solid tumors (eg lung, breast), hematological disorders (eg various leukemia & lymphoma disorders) and rare tumor types (eg neuroendocrine tumors, mesothelioma). Subscribe today to access  your target ThoughtLeader database for 2020 planning.

Precision ThoughtLeader identification and mapping

Our intuitive dashboard gives clients direct access to MDoutlook’s ThoughtLeader Attribute DialTM . Driven by our proprietary technology and transparent algorithms, clients can manipulate the detailed information to get access to different data sets and results based on changing inputs to match your business needs.

Click on image to enlarge

Our unique peer nomination process helps clients refine their identification of ThoughtLeaders highly regarded by their peers, especially those with more influence, those beyond the “top 50” and interest groups such as “Rising Stars”. Obtaining this information is easy and our dashboard enables clients to have all information in one place at their fingertips.

Our infographics allow user friendly access to ThoughtLeader information. Striving to meet client needs, we recently enhanced our dashboard functionality with newly created peer nomination maps allowing greater interactivity for clients to query the data and spot different ThoughtLeader connections.

For one of our clients, this has proved particularly impactful when uncovering early adopters for a specific cancer treatment when estimating treatment volumes and identifying high volume treaters.

Supporting all your ThoughtLeader activities

Whether you are engaging with ThoughtLeaders digitally, personally, or on the phone, we support you on your knowledge journey. We provide readily available expert insights and ThoughtLeader identification that will make your advisory councils, expert calls, congresses, and virtual engagements a success! At MDoutlook, we help clients to leverage ThoughtLeaders throughout the commercialization lifecycle of a compound and provide meaningful insights across functions to boost both opportunities and revenues.

Meet us at ASH

Let’s take your next step together by arranging a meeting at the ASH annual meeting (7th to 10th December) in Orlando or arranging a more convenient date/time to scope out your future success.

For further discussion or to arrange a meeting, please contact [email protected] or call +1.404.496.4136.

Master your post-conference follow-up

Measuring the impact of data announcements is of importance, tracking follow-up activity from a conference is of even greater importance and should not be overlooked when assessing the overall influence and reach of your messages.

Having helped numerous biopharmaceutical companies track impact from their messaging activities, our experienced team shares insights.

Tracking your impact post-conference matters

Having a data announcement at a conference (such as ESMO) can speak volumes. However, following a client survey of 147 US oncologists, we tracked impact from the messaging activity and observed little difference with attention captured at conferences when compared to post-conference. This pattern reflects what is normally seen in the market.

Click on image to enlarge

About half (n=75) of the US oncologists who did not attend ESMO rate their awareness of the news from ESMO as relatively high.

Nearly two-thirds of academic non-attendees rate their awareness of ESMO results as high or very high and by comparison, still almost half of US community oncologists rated their level of awareness on a similar basis. Attending conferences is still seen as valuable for new data announcements, but in an age of instant communications, attendance is not required to stay up to date.

Learning from colleagues

Click on image to enlarge

In another study, we helped a client track the impact of a hematology announcement by assessing the source and reach of results learned among oncologists from different nationalities who did not attend the conference. A higher proportion of (71%) EU oncologists who did not attend the conference learned of the results from a colleague who did attend compared to US oncologists (56%).

Biopharmaceutical companies need reliable partners with winning expertise and experience knowing what it takes to master these trends. In a highly competitive space where hyper-targeting is essential, MDoutlook provides clients with the right mix of agile assets, value solutions, and professional customer access to drive successful precision engagement with your most relevant customers in oncology, hematology, and rare diseases.

 

Meet us at ASH

We deliver value to our clients by engaging the right professional customers to inform the clients’ business decisions and commercialization strategies of their assets in the right way throughout the product cycle.

Let’s take your next step together by arranging at the ASH annual meeting (7th to 10th December) in Orlando or arranging a more convenient date / time to scope out your future success!

For further discussion or to arrange a meeting, please contact [email protected] or call +1.404.496.4136.

Hyper-targeting Oncologists

Whilst the importance of conferences such as ASCO and ASH are acknowledged this mantle is shared more than ever today.

ESMOs importance has grown significantly in recent years both in terms of size and diversity of audience as well as its reach as a global platform (e.g. more US healthcare professionals following ESMO online). In 2018, ESMO attracted nearly 28,000 attendees from 137 countries and over 3,000 submitted abstracts compared to 16,000 attendees from 127, and just over 2,000 submitted abstracts from the 2012 ESMO conference.

There has also been a noticeable rise in the importance of highly targeted disease-focused conferences such as EHA, IASLC, ICML, increased number of breakout meetings under the auspices of ASCO and ESMO (focusing on one cancer), and other similar scientific conferences with their increased importance as a platform for the dissemination of new data, meetings, exchange and reach to a global audience.

Hyper-targeting the right audience

With this in mind, biopharmaceutical companies need reliable agency partners with winning expertise and experience knowing what it takes to master these trends. In a highly competitive space where hyper-targeting is essential, MDoutlook provides clients with the right mix of agile assets, value solutions, and professional customer access to drive successful precision engagement with your most relevant customers in oncology, hematology, and rare diseases.

In a recent project, we measured the impact of our client’s new data announcements by interviewing oncologists in a rare disease area attending the International Congress on Malignant Lymphomas (ICML) in Lugano. The challenge was even greater due to the timing of the meeting, immediately following EHA and the need to engage oncologists based in the US and attending this highly focused European meeting.

Whether you are assessing the impact of data announcements or have another project in mind that requires hyper-targeting of your professional customers, we can enable your success by utilizing our proprietary assets and access to the world’s largest verified community of >120,000 treaters and experts in oncology, hematology, and rare diseases. This community is enriched through physician self-reported characteristics, and external adapters that are carefully and meaningfully applied through machine-learning and AI.

Meet us

We constantly deliver value to our clients by engaging the right professional customers to inform the clients’ business decisions and commercialization strategies of their assets in the right way throughout the product lifecycle.

Let’s take your next step together by arranging a meeting at your offices to scope out your future success!

For further discussion or to arrange a meeting, please contact [email protected] or call +1.404.496.4136.

The treatment landscape for prostate cancer is changing

Cabazitaxel was presented as an option for men with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after treatment with docetaxel and an androgen signaling-targeted agent according to data presented at ESMO 2019.

The results showed a significant survival benefit for Cabazitaxel in third line over enzalutamide or abiraterone where patients had previously undergone treatment with one of the 2nd generation antiandrogens and docetaxel.

Impact of announcement

There was a general perception among prostate cancer ThoughtLeaders at ESMO 2019 that Cabazitaxel could become a new standard in mCRPC post-docetaxel and 2nd generation antiandrogen. Cabazitaxel is already widely available in many countries aiding the anticipated changes in treatment practices and guidelines. Contrary to current standard practices, switching to novel hormonal agents has been shown to be much less effective.

Our work with prostate cancer treating clinicians

Click to enlarge

Our work with prostate cancer treating clinicians (see slide for details of our track record and robust prostate cancer treating community) suggests that there will be some significant resistance to change treatment paradigms by cancer treaters especially amongst urologists. In past studies, cancer treaters were less likely to use chemotherapy due to perceived side effects and more likely to use novel hormonal agents despite the lack of supporting evidence especially in older patients. What is your take on the new data presented at ESMO 2019? Let’s set-up a call to further discuss.

Beyond prostate cancer, we offer rich experience, expertise and robust treaters and experts access in all solid, hematological & rare cancers.

Meet us

Let’s take your next step together by arranging a meeting at your offices to scope out your future success!

For further discussion or to arrange a meeting, please contact [email protected] or call +1.404.496.4136.